

Our Pipeline

Inflammation

Oncology

Hematology

ABP 798 (biosimilar rituximab)

ABP 710 (biosimilar infliximab)

ABP 494 (biosimilar cetuximab)

ABP 959 (biosimilar eculizumab)

Monoclonal antibody that specifically binds to the complement protein C5

Reference product primary conditions:

Paroxysmal nocturnal hemoglobinuria

Atypical hemolytic uremic syndrome

Generalized myasthenia gravis

ABP 980 (biosimilar trastuzumab)

(/PRODUCTS/APPROVED-PRODUCTS/) (../CLINICAL-TRIALS/)

PREVIOUS:
APPROVED PRODUCTS

NEXT:
CLINICAL TRIALS

© 2019 Amgen Inc. All rights reserved.

Privacy and Terms (<http://www.amgen.com/privacy-statement/>) | **Contact Us (</contact-us/>)** |
Site Map (</site-map/>)

 (<https://twitter.com/AmgenBiosim>)  (<https://www.youtube.com/user/Amgen>)
(<http://www.amgen.com/>)